Mandate

Vinge advises Eleda in connection with the acquisition of Gatu och Väg Väst AB

Vinge has advised Eleda Infra Services Group (“Eleda”) on the acquisition of Gatu och Väg Väst AB (“GVV”).

GVV is based in Gunnilse and conducts construction and contracting operations in the south western Sweden, focusing on concrete maintenance work on, inter alia, bridges, power plants and port facilities. GVV has approximately 70 employees and yearly sales of around SEK 240 million. The company’s management team will continue in their respective operational management roles and become shareholders of the Eleda group.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

Vinge’s team consisted primarily of partner Christina Kokko and associates Michaela Cronemyr and Carl Fredrik Wachtmeister (M&A), Isak Willborg (Agreements), Ebba Svenburg (Employment), Frida Ställborn (Real Property & Environment), Johan Wahlbom and Joel Kokko (Competition), Tove Lövgren Frisk (Compliance) and Carl Bruneheim (VDR-specialist).

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024